Pressure builds against antitrust activity by pharma firms
This article was originally published in SRA
Executive Summary
Recent developments in Europe and the US show that the screw is clearly tightening on anticompetitive activity by the pharmaceutical industry on both sides of the Atlantic.
You may also be interested in...
Slovakia Becomes Second EU Country To OK Use Of Russian Vaccine
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
EU Launches ‘Structured Dialog’ To Thrash Out Supply Chain Concerns
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
And The UK's First 'Innovation Passport' Goes To... MSD's Rare Disease Drug Belzutifan
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: